» Articles » PMID: 24583195

A Novel Method to Measure HLA-DM-susceptibility of Peptides Bound to MHC Class II Molecules Based on Peptide Binding Competition Assay and Differential IC(50) Determination

Overview
Publisher Elsevier
Date 2014 Mar 4
PMID 24583195
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

HLA-DM (DM) functions as a peptide editor that mediates the exchange of peptides loaded onto MHCII molecules by accelerating peptide dissociation and association kinetics. The relative DM-susceptibility of peptides bound to MHCII molecules correlates with antigen presentation and immunodominance hierarchy, and measurement of DM-susceptibility has been a key effort in this field. Current assays of DM-susceptibility, based on differential peptide dissociation rates measured for individually labeled peptides over a long time base, are difficult and cumbersome. Here, we present a novel method to measure DM-susceptibility based on peptide binding competition assays performed in the presence and absence of DM, reported as a delta-IC(50) (change in 50% inhibition concentration) value. We simulated binding competition reactions of peptides with various intrinsic and DM-catalyzed kinetic parameters and found that under a wide range of conditions the delta-IC(50) value is highly correlated with DM-susceptibility as measured in off-rate assay. We confirmed experimentally that DM-susceptibility measured by delta-IC(50) is comparable to that measured by traditional off-rate assay for peptides with known DM-susceptibility hierarchy. The major advantage of this method is that it allows simple, fast and high throughput measurement of DM-susceptibility for a large set of unlabeled peptides in studies of the mechanism of DM action and for identification of CD4+ T cell epitopes.

Citing Articles

Developability considerations for bispecific and multispecific antibodies.

Amash A, Volkers G, Farber P, Griffin D, Davison K, Goodman A MAbs. 2024; 16(1):2394229.

PMID: 39189686 PMC: 11352713. DOI: 10.1080/19420862.2024.2394229.


CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.

Baumgaertner P, Schmidt J, Costa-Nunes C, Bordry N, Guillaume P, Luescher I Front Immunol. 2022; 13:973986.

PMID: 36032094 PMC: 9399405. DOI: 10.3389/fimmu.2022.973986.


Impact of HLA-DR Antigen Binding Cleft Rigidity on T Cell Recognition.

Szeto C, Bloom J, Sloane H, Lobos C, Fodor J, Jayasinghe D Int J Mol Sci. 2020; 21(19).

PMID: 32992915 PMC: 7582474. DOI: 10.3390/ijms21197081.


A Missing Switch in Peptide Exchange for MHC Class II Molecules.

Freund C, Hofer T Front Immunol. 2019; 10:2513.

PMID: 31708929 PMC: 6820466. DOI: 10.3389/fimmu.2019.02513.


HLA-DO Modulates the Diversity of the MHC-II Self-peptidome.

Nanaware P, Jurewicz M, Leszyk J, Shaffer S, Stern L Mol Cell Proteomics. 2018; 18(3):490-503.

PMID: 30573663 PMC: 6398211. DOI: 10.1074/mcp.RA118.000956.


References
1.
Belmares M, Busch R, Wucherpfennig K, McConnell H, Mellins E . Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J Immunol. 2002; 169(9):5109-17. DOI: 10.4049/jimmunol.169.9.5109. View

2.
Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M . Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics. 2010; 11:568. PMC: 2998531. DOI: 10.1186/1471-2105-11-568. View

3.
Narayan K, Chou C, Kim A, Hartman I, Dalai S, Khoruzhenko S . HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes. Nat Immunol. 2006; 8(1):92-100. PMC: 3019572. DOI: 10.1038/ni1414. View

4.
Call M, Xing X, Cuny G, Seth N, Altmann D, Fugger L . In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. J Immunol. 2009; 182(10):6342-52. PMC: 2695398. DOI: 10.4049/jimmunol.0803464. View

5.
Hall F, Rabinowitz J, Busch R, Visconti K, Belmares M, Patil N . Relationship between kinetic stability and immunogenicity of HLA-DR4/peptide complexes. Eur J Immunol. 2002; 32(3):662-70. DOI: 10.1002/1521-4141(200203)32:3<662::AID-IMMU662>3.0.CO;2-5. View